Abstract
Co-mutation-based subtyping of Chinese patients with gastric cancer.
Author
person
He Huang
The First Hospital of Shanxi Medical University, Shanxi, China
info_outline
He Huang, Zhimin Wang, Hao Chen, Yafei Cheng, Hui Liu, Shaoxiong Bai, Yaoliang Huo, Yanwu Zeng, Leilei Lu
Full text
Authors
person
He Huang
The First Hospital of Shanxi Medical University, Shanxi, China
info_outline
He Huang, Zhimin Wang, Hao Chen, Yafei Cheng, Hui Liu, Shaoxiong Bai, Yaoliang Huo, Yanwu Zeng, Leilei Lu
Organizations
The First Hospital of Shanxi Medical University, Shanxi, China, Shanghai OrigiMed Co., Ltd, Shanghai, China
Abstract Disclosures
Research Funding
No funding received
None.
Background:
The incidence of gastric cancer is decreasing globally, in contrast, that of Chinese patients has been increased from 35.9% to 48.3%. In-depth investigation of the characteristic of Chinese gastric cancer patients could help to understand the disease mechanism and improve the treatment of gastric cancer.
Methods:
Tumor tissues were obtained from 96 Chinese gastric cancer patients and tested by high-coverage ( > 1000x) panel sequencing containing 624 cancer-related genes. Genomic mutations including substitutions, insertions, deletions, rearrangements, fusions, and copy number variations were called. Genes were clustered based on their co-mutation relationship in all samples. Patients with gene mutations in each cluster were classified into corresponding groups. The properties of each patient group were characterized, including genomic features, age, gender, stage, LAUREN type, and grade.
Results:
The most mutated genes were
TP53
,
ERBB4
,
LRP1B
, and
CDH1
in our cohort. A higher proportion of female patients had
TP53
mutations compared to male patients. Mutations in
ALK
,
KMT2C
, and
LRP2
were positively associated with microsatellite-instable, and that in
ERBB4
and
PIK3CA
were positively associated with high tumor mutation burden (TMB). Four gene clusters (1, 2, 3, and 4) were identified based on the co-mutation relationship between genes. Cluster 1 included
FAT4
,
APC
,
OBSCN
, and
GATA3
; Cluster 2 included
FGF3
,
CCND1
,
FGF19
, and
GATA4
; Cluster 3 included
BLK
,
FAM135B
, and
DLC1
; and Cluster 4 included
ATRX
,
KMT2D
,
STAG2
, and
EGFR
. Patients were classified into the four patient groups (I, II, III, and IV) accordingly when mutations in the corresponding gene cluster were found. Further association analysis indicated that: Group I was associated with adenocarcinoma subtype; Group II was negatively associated with LAUREN type 2; Group III was associated with high TMB; Cluster IV was associated with microsatellite-instable.
Conclusions:
This study utilized gene co-mutations to classify gastric cancer patients into subgroups with unique clinical characteristics. Further study on the etiology, treatment, and prognosis of these groups of patients is needed.
2 organizations
23 drugs
1 target
Organization
The First Hospital of Shanxi Medical UniversityOrganization
Shanghai OrigiMed Co., Ltd., Shanghai, ChinaDrug
TP53Drug
ERBB4Drug
LRP1BDrug
CDH1Drug
MelphalanDrug
KMT2CDrug
LRP2Drug
PIK3CADrug
FAT4Drug
APC R1468*Drug
OBSCNDrug
GATA3Drug
FGF3Drug
CCND1Drug
FGF19Drug
GATA4Drug
BLKDrug
FAM135BDrug
DLC1Drug
ATRXDrug
KMT2DDrug
STAG2